Latest Breaking News On - David soergel - Page 1 : comparemela.com

Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with C3G every year

Novartis: presented results for kidney disease

Novartis has presented the results of a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A receptor antagonist, in patients with.

Novartis releases Phase III data on its investigational oral therapy to treat chronic kidney disease

Novartis' atrasentan shows to reduce proteinuria in Phase III IgAN trial

Atrasentan’s safety profile in the trial was deemed favourable, aligning with previous data.

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label.